Glenmark s Ryaltris® nasal spray now approved in Europe for the first line treatment of allergic rhinitis in patients over 12 years of age
News provided by
Share this article
Share this article
The launch will ensure much-needed access to a novel fixed-dose combination nasal spray for this chronic condition
This marks Glenmark s first innovative product approval in the European Union
MUMBAI, India, April 26, 2021 /PRNewswire/ Glenmark Pharmaceuticals Limited, a research-led, global integrated pharmaceutical company, is concluding the final, national phase of its marketing approval application process to enable launch of its innovative nasal spray in 17 countries in the European Union. Ryaltris
Ionis initiates pivotal clinical study of novel antisense medicine to treat patients with Alexander disease
- Innovative therapy targeting the root cause of the disease has received orphan drug designation by the U.S. FDA and European Medicines Agency
- ION373 is one of Ionis wholly owned rare disease medicines the company plans to commercialize
News provided by
Share this article
Share this article
CARLSBAD, Calif., April 20, 2021 /PRNewswire/ Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) today announced it has initiated a pivotal clinical study of ION373 in patients with Alexander disease, a rare and generally fatal neurological disorder. Alexander disease patients experience progressive deterioration, leading to severe disability and loss of independence. Childhood onset is associated with more serious disease, with patients rarely surviving beyond adolescence. Alexander disease is caused by a genetic mutation that leads to overproduction and toxic accumulation of glial fi
Co-Diagnostics, Inc.
(Nasdaq: CODX), a molecular diagnostics company with a unique, patented platform for the development of diagnostic tests, announced today that its Logix Smart™ COVID-19 Test Kit was used by Australian researchers to demonstrate rapidly deployable mobile molecular diagnostics support for remote locations, with the peer-reviewed results published in the
Journal of Medical Microbiology.
The study was performed using readily available open-source equipment and materials that could be successfully operated in regional clinical laboratories, many of which are not currently equipped for molecular diagnostics. When tested on clinical samples, the sensitivity and specificity of the Company s test showed complete concordance with the comparison assay used in the study. The researchers also demonstrated an analytical sensitivity of 1010 viral copies per milliliter, which they found to be comparable to other tests used across Western Australia.
Spine BioPharma Announces Investment by Pacira Biosciences
Supports Clinical Advancement of Remedisc™ for Degenerative Disc Disease
News provided by
Share this article
Share this article
NEW YORK, April 20, 2021 /PRNewswire/ Spine BioPharma, LLC, a company committed to developing non-opiate, non-surgical therapies for the treatment of pain and disability from chronic low back pain caused by degenerative disc disease, today announced a $3 million investment by Pacira Biosciences in the form of a convertible note. The investment will support the further development of Remedisc, a first-in-class therapeutic for the treatment of degenerative disc disease. Pacira will make an additional $7 million investment predicated upon achieving certain prespecified milestones.
Share this article
Share this article
ENGLEWOOD, Colo., April 19, 2021 /PRNewswire/ Ampio Pharmaceuticals (NYSE American: AMPE), a biopharmaceutical company focused on the advancement of immunology-based therapies for prevalent inflammatory conditions for which there are limited treatment options, today announced findings of pre-clinical research demonstrating that Ampio s lead drug candidate, Ampion™, provides some of the same anti-inflammatory effects as the steroid dexamethasone but without the significant adverse events associated with steroids. Steroids such as dexamethasone are globally immunosuppressive, to both innate and adaptive immune systems, with effects that are beneficial in the short term and often harmful long-term, said David Bar-Or, M.D., Director and Founder of Ampio Pharmaceuticals.